Strides Arcolab gets US FDA nod for cancer treatment drugs

Pharma company Strides Arcolab’s unit Onco Therapies has received US Food and Drugs Administration (FDA) approval for Paclitaxel injection used to treat ovarian cancer, breast cancer and non-small cell lung cancer.
  • Language
  • App
  • Subscriptions
  • Specials
  • Sign-In
  • Register
GeStepAhead GrowMyMoney IThe Winning Leap SME Special
Moneycontrol

Home » News » Business

Sep 30, 2011, 11.10 AM | Source: Moneycontrol.com

Strides Arcolab gets US FDA nod for cancer treatment drugs

Pharma company Strides Arcolab’s unit Onco Therapies has received US Food and Drugs Administration (FDA) approval for Paclitaxel injection used to treat ovarian cancer, breast cancer and non-small cell lung cancer.

Like this story, share it with millions of investors on M3

Strides Arcolab gets US FDA nod for cancer treatment drugs

Pharma company Strides Arcolab’s unit Onco Therapies has received US Food and Drugs Administration (FDA) approval for Paclitaxel injection used to treat ovarian cancer, breast cancer and non-small cell lung cancer.

Post Your Comments

Share Cancel

Strides Arcolab gets US FDA nod for cancer treatment drugs
Moneycontrol Bureau

Pharma company Strides Arcolab ’s unit Onco Therapies has received US Food and Drugs Administration (FDA) approval for Paclitaxel injection used to treat ovarian cancer, breast cancer and non-small cell lung cancer.

Onco Therapies also received tentative approval for Oxaliplatin injection, another chemotherapy drug used to treat cancer of the colon and rectum, Strides Arcolab said Friday.

Paclitaxel is among the products in the drug shortage list of the American Society of Health System Pharmacists and the US FDA, and the company will launch the product immediately, it said.

The US market for generic Paclitaxel is about USD 46 million, while Oxaliplatin injection has a US market of USD 1.4 billion, Strides Arcolab said citing IMS Health data.

Both Paclitaxel and Oxaliplatin are part of Strides Arcolab’s oncologIs y drugs portfolio licensed to Pfizer for the US market, it said.

Global Pharma major Pfizer had entered into an agreement in 2010 to sell Strides Arcolab’s cancer treatment drugs in the US.

Strides Arcolab shares were traded up 0.6% at Rs 356.95 on NSE in morning trade on Friday.

Buy, Hold, Sell ? Hear it first on M3
Strides Arcolab gets US FDA nod for cancer treatment drugs

See all

Get started using your favorite social network

or

Login using moneycontrol ID

Username
Password

Need help logging in? Reset password.

Don´t have an account? Sign Up

Get started using your favorite social network

or

Simply sign up using this short form

* mandatory

UserName*

Username should be atleast 4 character

Password*

Password should be 8 or more characters,
atleast 1 number, 1 symbol & 1 upper case letter

Alert

Your Password should contain
  • 8 or more characters
  • At least 1 number
  • At least 1 symbol
  • At least 1 upper case letter
Confirm Password*
Email
Already have an account? Login